Bumper Offer - Urjas oil Just @ Rs. 1
A Ret 0.025% Gel is a prescription medicine that is available as a Gel. Primarily, it is used for the treatment of Pimples.
The correct dosage of A Ret 0.025% Gel depends on the patient's age, gender, and medical history. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Detailed information has been provided in the dosage section.
The most common side effects of A Ret 0.025% Gel are Fluid retention. Some other side effects of A Ret 0.025% Gel have been listed ahead. These side effects of A Ret 0.025% Gel are usually temporary and subside with the completion of treatment. However, if these continue for a longer time, consult your doctor right away.
Furthermore, you should know that effect of A Ret 0.025% Gel is Moderate for pregnant women and Severe for women who are breastfeeding. Warnings related to A Ret 0.025% Gel's effects on the liver, heart and kidney, if any, have been listed below.
A Ret 0.025% Gel is contraindicated in people with pre-existing medical conditions like Allergy, Eczema as it can result in adverse effects. Other contraindications of A Ret 0.025% Gel have been discussed in the sections ahead.
Besides this, A Ret 0.025% Gel may also have severe interaction with some medicines. See below for a complete list.
You should also be aware that A Ret 0.025% Gel is not safe while driving, and is not addiction.
A Ret 0.025% Gel is used to treat the following -
Main Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
Based on research, the following side effects have been observed when A Ret 0.025% Gel is used -
Severe
Moderate
Mild
Common
Is the use of A Ret 0.025% Gel safe for pregnant women?
A Ret can cause unwanted side effects in pregnant women. If you experience any side effects, stop taking A Ret right away. Take your doctor's advice before taking it again.
Is the use of A Ret 0.025% Gel safe during breastfeeding?
Women who are breastfeeding may experience severe harmful effects after taking A Ret. It should only be taken after medical advice.
What is the effect of A Ret 0.025% Gel on the Kidneys?
Information about safety of A Ret for kidney is not available since scientific research on this topic is yet to be done.
What is the effect of A Ret 0.025% Gel on the Liver?
There may be an adverse effect on the liver after taking A Ret. If you observe any side effects on your body then stop taking this drug. Take this medicine again only if your doctor advises you to do so.
What is the effect of A Ret 0.025% Gel on the Heart?
A Ret is not harmful for the heart.
A Ret 0.025% Gel should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
If you are suffering from any of the following diseases, you should not take A Ret 0.025% Gel unless your doctor advises you to do so -
Is this A Ret 0.025% Gel habit forming or addictive?
No, there is no any evidence that A Ret 0.025% Gel is addictive.
Is it safe to drive or operate heavy machinery when consuming?
After taking A Ret 0.025% Gel you may feel sleepy. So it is not advised to perform these activities.
Is it safe?
A Ret 0.025% Gel is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
No, the use of A Ret 0.025% Gel in mental disorders is not effective.
Interaction between Food and A Ret 0.025% Gel
It is safe to take A Ret 0.025% Gel with food.
Interaction between Alcohol and A Ret 0.025% Gel
Information about the interaction of A Ret 0.025% Gel and alcohol is not currently available because this topic has not been researched yet.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 718-719
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 869
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Retin-A Micro (tretinoin)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Retin-A® (tretinoin)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Renova® (tretinoin)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vesanoid® (tretinoin)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 718-719
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 869
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Retin-A Micro (tretinoin)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Retin-A® (tretinoin)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Renova® (tretinoin)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vesanoid® (tretinoin)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 718-719
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 869
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Retin-A Micro (tretinoin)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Retin-A® (tretinoin)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Renova® (tretinoin)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vesanoid® (tretinoin)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 718-719
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 869
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Retin-A Micro (tretinoin)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Retin-A® (tretinoin)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Renova® (tretinoin)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vesanoid® (tretinoin)
